 | Joel Lexchin Professor Emeritus - York University Sciences politiques |
-
02.09.2014-29.10.2014
Private Profits vs Public Policy: The Pharmaceutical Industry and the Canadian State
The main objective of this project is to produce a book length manuscript that explores the historical development and current manifestation of the inter-relationship between the pharmaceutical industry and the Canadian state in order to understand the political, economic and social dimensions through which these two entities interact. The secondary objectives are to deepen the academic debate around how this relationship should evolve in the future taking into account both public and private interests and to try and gain an understanding about how this relationship will affect the way that pharmaceuticals are developed, approved, marketed, used and paid for in Canada.
Joel Lexchin received his MD from the University of Toronto in 1977 and until April 2022 was an emergency physician at the University Health Network. He is a Professor Emeritus in the School of Health Policy and Management at York University and an Associate Professor in the Department of Family and Community Medicine at the University of Toronto. From 1992-94 he was a member of the Ontario Drug Quality and Therapeutics Committee and he was the chair of the Drugs and Pharmacotherapy Committee of the Ontario Medical Association from 1997-99. He has been a consultant for the province of Ontario, various arms of the Canadian federal government, the World Health Organization, the government of New Zealand and the Australian National Prescribing Service. He is the author or co-author of over 270 peer-reviewed articles on topics such as physician prescribing behaviour, pharmaceutical patent issues, the drug approval process and prescription drug promotion. He wrote the first draft of his book Private Profits vs Public Policy: The Pharmaceutical Industry and the Canadian State during a residency at the Brocher Foundation and in September 2016 the book was published by University of Toronto Press. His second book Doctors in Denial: Why the Canadian Medical Profession and the Pharmaceutical Industry Are Too Close for Comfort was published in 2017.
Précédent